<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002745</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02791</org_study_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>CLB-9551</secondary_id>
    <secondary_id>CDR0000064666</secondary_id>
    <nct_id>NCT00002745</nct_id>
  </id_info>
  <brief_title>Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma</brief_title>
  <official_title>PHASE II STUDY OF 9-AMINOCAMPTOTHECIN (9-AC/DMA, NSC# 603071) IN PREVIOUSLY TREATED HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA: IWF GRADES A-H</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of aminocamptothecin in treating patients who have&#xD;
      refractory or recurrent Hodgkin's disease or non-Hodgkin's lymphoma. Drugs used in&#xD;
      chemotherapy use different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Evaluate the response rate and duration of response to aminocamptothecin (9-AC) in&#xD;
      patients with refractory or relapsed Hodgkin's disease or non-Hodgkin's lymphoma.&#xD;
&#xD;
      II. Assess the toxicity of 9-AC in these patients. III. Validate a preliminary&#xD;
      pharmacodynamic model relating total 9-AC concentration, albumin, and bilirubin to toxicity.&#xD;
&#xD;
      IV. Determine whether 9-AC concentrations correlate with response.&#xD;
&#xD;
      OUTLINE: Patients are stratified by disease histology (International Working Formulation&#xD;
      (IWF) A-C vs IWF D-F) and center.&#xD;
&#xD;
      Patients receive aminocamptothecin IV continuously on days 1-3. Treatment repeats every 2&#xD;
      weeks for a minimum of 3 courses in the absence of disease progression or unacceptable&#xD;
      toxicity. Patients who achieve stable disease, partial response (PR), or complete response&#xD;
      (CR) may receive 2 additional courses past best response (minimum of 6 courses if PR or CR).&#xD;
      Patients are followed every 6 months for 2 years, and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1996</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response</measure>
    <time_frame>2 years post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>day 1 of each cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9-AC/DMA concentrations</measure>
    <time_frame>Pre-treatment cycle 1 and just prior to completion of cycle 1</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>aminocamptothecin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aminocamptothecin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aminocamptothecin</intervention_name>
    <description>850 micrograms/square meter/day (total dose 2550 micrograms/square meter) via central venous catheter using infusion pump over 72 hours + one cycle Cycle repeated every 14 days for minimum of 6 cycles if partial or complete response</description>
    <arm_group_label>aminocamptothecin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically documented Hodgkin's disease (closed to accrual 4/15/2000) OR&#xD;
&#xD;
          -  Histologically documented non-Hodgkin's lymphoma (NHL) of one of the following&#xD;
             International Working Formulation (IWF) histologies:&#xD;
&#xD;
               -  Small lymphocytic (absolute lymphocyte count less than 5,000)&#xD;
&#xD;
               -  IWF A Follicular, predominantly small cleaved cell&#xD;
&#xD;
               -  IWF B Follicular mixed&#xD;
&#xD;
               -  IWF C Follicular large cell&#xD;
&#xD;
               -  IWF D* Diffuse small cleaved cell&#xD;
&#xD;
               -  IWF E* Diffuse mixed&#xD;
&#xD;
               -  IWF F* Diffuse large cell&#xD;
&#xD;
               -  IWF G* Large cell, immunoblastic&#xD;
&#xD;
               -  IWF H* * Accrual of patients with these diagnoses closed 4/15/2000&#xD;
&#xD;
          -  Pathology review required within 60 days of registration&#xD;
&#xD;
          -  Refractory to or relapsed after prior chemotherapy as follows:&#xD;
&#xD;
               -  Low-grade NHL (IWF A-C): 1 or 2 prior therapies&#xD;
&#xD;
               -  Intermediate-grade NHL (IWF D-H): 1 prior therapy (stratum closed 4/15/2000)&#xD;
&#xD;
               -  Hodgkin's disease: 1 or 2 prior therapies (stratum closed 4/15/2000)&#xD;
&#xD;
          -  Treatment with the same drugs on 2 different schedules considered 1 therapy&#xD;
&#xD;
          -  Measurable disease by physical exam or imaging studies&#xD;
&#xD;
          -  Mass larger than 1 x 1 cm&#xD;
&#xD;
          -  Documented progression required of previously irradiated lesions&#xD;
&#xD;
          -  The following are not considered measurable:&#xD;
&#xD;
               -  Ascites or pleural effusion&#xD;
&#xD;
               -  Bone marrow involvement&#xD;
&#xD;
               -  Positive barium studies&#xD;
&#xD;
               -  Bony disease (lytic lesions noted)&#xD;
&#xD;
               -  No mantle cell or transformed lymphoma&#xD;
&#xD;
               -  No parenchymal or leptomeningeal CNS disease&#xD;
&#xD;
          -  A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ.&#xD;
             The terminology of &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former&#xD;
             terminology of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol&#xD;
             uses the former terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Age: 18 and over&#xD;
&#xD;
          -  Performance status: CALGB 0-2&#xD;
&#xD;
          -  Unless hypersplenism or biopsy-proven bone marrow involvement:&#xD;
&#xD;
               -  Absolute granulocyte count at least 1,500/mm3&#xD;
&#xD;
               -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST no greater than 4 times normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  No suspected HIV infection&#xD;
&#xD;
          -  No second malignancy within past 5 years except:&#xD;
&#xD;
               -  Curatively treated carcinoma of the cervix&#xD;
&#xD;
               -  Curatively treated basal cell skin cancer&#xD;
&#xD;
               -  No uncontrolled infection or other serious medical condition&#xD;
&#xD;
               -  No psychiatric condition that precludes informed consent&#xD;
&#xD;
               -  Not pregnant or nursing&#xD;
&#xD;
               -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior allogeneic or autologous bone marrow transplant&#xD;
&#xD;
          -  More than 3 weeks since chemotherapy (6 weeks since nitrosoureas, melphalan, or&#xD;
             mitomycin)&#xD;
&#xD;
          -  No prior camptothecin&#xD;
&#xD;
          -  More than 3 weeks since radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy L. Bartlett, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Washington University Siteman Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Barnard Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper Cancer Institute</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bartlett NL, Johnson JL, Wagner-Johnston N, Ratain MJ, Peterson BA; Cancer and Leukemia Group B. Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer Chemother Pharmacol. 2009 Apr;63(5):793-8. doi: 10.1007/s00280-008-0803-x. Epub 2008 Jul 23.</citation>
    <PMID>18648813</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2004</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

